Association between Antidiabtic Medications and Worsening of Parkinson’s Symptoms: A Case Report
International Journal of Medical and Pharmaceutical Case Reports,
Introduction: Parkinson's disease (PD) is one of the most prevalent neurologic disorders, leading to progressive disability; it is characterized by tremors, slow movements, stiffness in arms and legs, and balance impairment; PD symptoms can be slowed but not stopped by treatment such as a combination of Carbidopa/ Levodopa. Although it's widely used for PD, it risks dyskinesia, orthostatic hypotension, and dizziness. The prevalence of PD in Saudi Arabia has been estimated to be 27 per 100,000 populations, and the occurrence of PD in the U.S. is approximately 20 cases per 100,000 people per year.
Case presentation: A 61 years old male presented with worsening PD symptoms, especially dysarthria symptom; he had a history of diabetes with A1C of 8.5%, on metformin, insulin glargine, liraglutide, and linagliptin, with good adherence, and he had a history of Parkinson on levodopa/carbidopa. Even there are no known drug-drug interactions between antidiabetic medication and levodopa/ carbidopa, he reported that coadministration of antidiabetic medications with levodopa/carbidopa cause PD symptoms worsening, especially dysarthria worsening. This drug-drug interaction was noticed when the patient tried to stop all of his antidiabetic medication except insulin mixtard, when he noticed dysarthria symptoms improved. He is currently on insulin mixtard for diabetes with an A1C of 6.7%.
Conclusion: Unintentional drug-drug interaction poses a challenge to the healthcare provider, so this report highlights the importance of adverse drug-drug interaction of antidiabetic with levodopa/carbidopa, its presentation, and management.
- Parkinson’s disease
- Diabetes mellitus
- antidiabetic medication.
How to Cite
Stacy M, et al. “End-of-dose Wearing Off in Parkinson Disease: A 9-Question Survey Assessment,” Clin. Neuropharmacol. 2006; 29:6.[Online].
Wan Y, et al. Wearing-off Identification in Parkinson’s Disease: The shapd-woq Study,” Frontiers in Neurology. 2020;11: 116. [Online].
Athauda D, Foltynie T. “Insulin resistance and Parkinson’s disease: A new target for disease modification?,” Prog. Neurobiol. 2016;145–146,98–120.
Lang AE, Lozano AM. Parkinson’s disease,” N. Engl. J. Med. 1998;339(16): 1130–1143.
Eisenbarth GS. “Type I diabetes mellitus,” N. Engl. J. Med. 1986;314(21): 1360–1368.
Das RR, Unger MM. Diabetes and Parkinson disease: A sweet spot?” AAN Enterprises; 2018.
Hassan A, Sharma Kandel R, Mishra R, Gautam J, Alaref A, Jahan N. Diabetes Mellitus and Parkinson’s Disease: Shared Pathophysiological Links and Possible Therapeutic Implications,” Cureus. 2020;12(8):e9853–e9853.
Camargo Maluf F, Feder D, Alves de Siqueira Carvalho A. “Analysis of the Relationship between Type II Diabetes Mellitus and Parkinson’s Disease: A Systematic Review,” Park. Dis. 2019: 4951379, 2019,
Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J. “Type 2 diabetes and the risk of Parkinson’s disease,” Diabetes Care. 2007;30(4):842–847.
De Pablo-Fernandez E, Goldacre R, Pakpoor J, Noyce AJ, Warner TT. “Association between diabetes and subsequent Parkinson disease: a record-linkage cohort study,” Neurology. 2018;91 (2):e139–e142.
Abstract View: 127 times
PDF Download: 21 times